Paolo Tarantino: Monitoring ADC-related interstitial lung disease

Paolo Tarantino shared a post on LinkedIn:

“More sensitive ways are needed to monitor for ADC-related interstitial lung disease. Could liquid biopsy help?

Check out our proof-of-concept study of ILD monitoring through lung-specific cfDNA, used as a surrogate for pulmonary damage.”

Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA

Authors: A. Grinshpun, A. Zick, T. Perri, A. Naim, Paolo Tarantino,  S.M. Tolaney, J. Magenheim and O. Fridlich.

Source: Paolo Tarantino/LinkedIn

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.